Wolfe Research Initiates Coverage On Celldex Therapeutics with Outperform Rating
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has initiated coverage on Celldex Therapeutics with an Outperform rating, indicating a positive outlook for the company's stock.
June 11, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research has initiated coverage on Celldex Therapeutics with an Outperform rating, suggesting a positive outlook for the stock.
An Outperform rating from a reputable firm like Wolfe Research typically indicates strong confidence in the company's future performance, which can lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100